癌症化疗相关的恶心与呕吐：理论与实践中的药物管理
Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.
作者信息
Antonarakis E S, Hain R D W
机构信息
University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK.
出版信息
Arch Dis Child. 2004 Sep;89(9):877-80. doi: 10.1136/adc.2003.037341.
Abstract
The function of cytotoxics is to damage cells, and it makes teleological sense for the body to expel them as soon after ingestion as possible. Ideally, from the body's point of view, they should simply be avoided, and it is not surprising that the experience of chemotherapy induced nausea and vomiting (CINV) is powerfully aversive. Nausea and vomiting were once among the most intractable and unpleasant experiences of a child undergoing treatment for cancer.
摘要
细胞毒性药物的作用是损伤细胞，身体尽快在摄入后将它们排出具有目的论意义。理想情况下，从身体的角度来看，应该完全避免接触这些药物，化疗引起的恶心和呕吐（CINV）体验具有强烈的厌恶感也就不足为奇了。恶心和呕吐曾经是癌症患儿在接受治疗过程中最棘手、最难受的经历之一。
相似文献
1
Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.
Arch Dis Child. 2004 Sep;89(9):877-80. doi: 10.1136/adc.2003.037341.
2
Chemotherapy-induced nausea and vomiting.
Cancer J. 2008 Mar-Apr;14(2):85-93. doi: 10.1097/PPO.0b013e31816a0f07.
3
Antiemetic drugs.
Medsurg Nurs. 2009 Sep-Oct;18(5):309-13; quiz 314.
4
Chemotherapy-induced nausea and vomiting.
N Engl J Med. 2008 Jun 5;358(23):2482-94. doi: 10.1056/NEJMra0706547.
5
Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
J Support Oncol. 2007 May;5(5 Suppl 3):1-9.
6
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Clin Adv Hematol Oncol. 2004 May;2(5):284-9.
7
Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
J Support Oncol. 2003 Jul-Aug;1(2):89-103.
8
Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists.
Clin Adv Hematol Oncol. 2006 Jul;4(7):507-8.
9
Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Oncol Nurs Forum. 1992 Jun;19(5):791-5.
10
Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
J Oncol Pharm Pract. 2007 Mar;13(1):57-8. doi: 10.1177/1078155207077265.
引用本文的文献
1
Medicinal Plants for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Antiemetic, Chemosensitizing, and Immunomodulatory Mechanisms.
Ther Clin Risk Manag. 2025 Jul 31;21:1187-1218. doi: 10.2147/TCRM.S531645. eCollection 2025.
2
Comparison of oral aprepitant and intravenous fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric oncology patients: a randomized phase III trial.
Transl Pediatr. 2024 Jan 29;13(1):110-118. doi: 10.21037/tp-23-598. Epub 2024 Jan 12.
3
Feeding Intolerance in Children with Severe Impairment of the Central Nervous System: Strategies for Treatment and Prevention.
Children (Basel). 2017 Dec 22;5(1):1. doi: 10.3390/children5010001.
4
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.
Cochrane Database Syst Rev. 2016 Feb 2;2(2):CD007786. doi: 10.1002/14651858.CD007786.pub3.
5
Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting.
J Adv Pharm Technol Res. 2012 Oct;3(4):202-9. doi: 10.4103/2231-4040.104710.
本文引用的文献
1
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
J Clin Oncol. 2003 Nov 15;21(22):4112-9. doi: 10.1200/JCO.2003.01.095. Epub 2003 Oct 14.
2
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Cancer. 2003 May 1;97(9):2290-300. doi: 10.1002/cncr.11320.
3
In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy.
Bone. 2002 Aug;31(2):319-26. doi: 10.1016/s8756-3282(02)00822-0.
4
Chemotherapy-induced nausea and vomiting.
Clin J Oncol Nurs. 2002 Mar-Apr;6(2):94-102. doi: 10.1188/02.CJON.94-102.
5
Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Pediatr Hematol Oncol. 2001 Sep;18(6):397-406. doi: 10.1080/088800101316922029.
6
Delayed nausea and vomiting in children receiving antineoplastics.
Med Pediatr Oncol. 2001 Aug;37(2):115-21. doi: 10.1002/mpo.1179.
7
A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
Pediatr Hematol Oncol. 2000 Sep;17(6):445-55. doi: 10.1080/08880010050120791.
8
Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
J Pediatr Hematol Oncol. 1999 Jul-Aug;21(4):274-83. doi: 10.1097/00043426-199907000-00007.
9
Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Med Pediatr Oncol. 1999 Aug;33(2):99-105. doi: 10.1002/(sici)1096-911x(199908)33:2<99::aid-mpo7>3.0.co;2-p.
10
Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):101-8. doi: 10.1080/088800199277425.
Zotero 插件